Astrana Health (NASDAQ:ASTH) Price Target Raised to $41.00 at Needham & Company LLC

Astrana Health (NASDAQ:ASTH) had its target price increased by Needham & Company LLC from $30.00 to $41.00 in a research note released on Friday, MarketBeat.com reports. They currently have a buy rating on the stock.

Other analysts have also recently issued research reports about the stock. Truist Financial boosted their target price on shares of Astrana Health from $37.00 to $38.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Zacks Research raised shares of Astrana Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, March 11th. Robert W. Baird boosted their target price on shares of Astrana Health from $37.00 to $40.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 15th. Weiss Ratings raised shares of Astrana Health from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Finally, BTIG Research boosted their target price on shares of Astrana Health from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $38.86.

Astrana Health Price Performance

Shares of Astrana Health stock opened at $39.30 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.40 and a debt-to-equity ratio of 1.25. Astrana Health has a twelve month low of $18.08 and a twelve month high of $39.90. The business has a 50-day moving average price of $27.38 and a 200 day moving average price of $25.67. The firm has a market cap of $2.19 billion, a PE ratio of 64.43 and a beta of 0.98.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.45. Astrana Health had a return on equity of 9.31% and a net margin of 0.86%.The firm had revenue of $965.10 million during the quarter, compared to analyst estimates of $949.21 million. During the same quarter in the previous year, the business earned $0.42 EPS. Astrana Health’s revenue for the quarter was up 55.6% compared to the same quarter last year. Sell-side analysts predict that Astrana Health will post 1.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Astrana Health

Institutional investors and hedge funds have recently bought and sold shares of the business. Diamond Hill Capital Management Inc. boosted its position in Astrana Health by 33.0% during the third quarter. Diamond Hill Capital Management Inc. now owns 361,264 shares of the company’s stock worth $10,242,000 after acquiring an additional 89,733 shares during the last quarter. Insight Wealth Strategies LLC acquired a new position in Astrana Health during the fourth quarter worth about $3,514,000. 325 Capital LLC boosted its position in Astrana Health by 34.6% during the third quarter. 325 Capital LLC now owns 1,193,953 shares of the company’s stock worth $33,849,000 after acquiring an additional 307,037 shares during the last quarter. SG Americas Securities LLC acquired a new position in Astrana Health during the third quarter worth about $1,062,000. Finally, Quantbot Technologies LP boosted its position in Astrana Health by 384.4% during the third quarter. Quantbot Technologies LP now owns 40,659 shares of the company’s stock worth $1,153,000 after acquiring an additional 32,265 shares during the last quarter. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Astrana Health

Here are the key news stories impacting Astrana Health this week:

• Positive Sentiment: Astrana Health beat first-quarter sales expectations, reporting revenue of $965.1 million versus the $949.2 million consensus, while EPS came in at $0.74, well above the $0.29 estimate. Revenue also rose 55.6% year over year, signaling strong operating momentum. Article title
• Positive Sentiment: The company’s full-year 2026 revenue guidance of $3.8 billion to $4.1 billion was issued near Wall Street expectations, which can support confidence that growth remains intact. Article title
• Positive Sentiment: Needham & Company raised its price target on ASTH to $41 from $30 and kept a buy rating, while BTIG Research lifted its target to $50 from $40 and also reiterated a buy rating. Those moves suggest analysts see more upside after the earnings beat.
• Neutral Sentiment: Investors are also digesting the earnings call transcript and presentation, which may provide additional detail on margins, guidance, and the company’s growth strategy.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.